QQQ   368.40 (-1.32%)
AAPL   144.18 (-1.86%)
MSFT   293.79 (-1.86%)
FB   348.56 (-1.25%)
GOOGL   2,812.17 (-1.13%)
TSLA   773.15 (-0.16%)
AMZN   3,351.30 (-2.17%)
NVDA   214.13 (-3.03%)
BABA   145.61 (+0.37%)
NIO   34.69 (-1.95%)
CGC   14.01 (+0.72%)
GE   106.29 (+2.40%)
MU   74.22 (+0.23%)
AMD   103.83 (-1.86%)
T   27.45 (+1.18%)
F   14.07 (+2.10%)
ACB   5.98 (+0.50%)
DIS   176.40 (+0.23%)
PFE   43.83 (-0.25%)
BA   227.69 (+2.85%)
BAC   43.29 (+2.73%)
QQQ   368.40 (-1.32%)
AAPL   144.18 (-1.86%)
MSFT   293.79 (-1.86%)
FB   348.56 (-1.25%)
GOOGL   2,812.17 (-1.13%)
TSLA   773.15 (-0.16%)
AMZN   3,351.30 (-2.17%)
NVDA   214.13 (-3.03%)
BABA   145.61 (+0.37%)
NIO   34.69 (-1.95%)
CGC   14.01 (+0.72%)
GE   106.29 (+2.40%)
MU   74.22 (+0.23%)
AMD   103.83 (-1.86%)
T   27.45 (+1.18%)
F   14.07 (+2.10%)
ACB   5.98 (+0.50%)
DIS   176.40 (+0.23%)
PFE   43.83 (-0.25%)
BA   227.69 (+2.85%)
BAC   43.29 (+2.73%)
QQQ   368.40 (-1.32%)
AAPL   144.18 (-1.86%)
MSFT   293.79 (-1.86%)
FB   348.56 (-1.25%)
GOOGL   2,812.17 (-1.13%)
TSLA   773.15 (-0.16%)
AMZN   3,351.30 (-2.17%)
NVDA   214.13 (-3.03%)
BABA   145.61 (+0.37%)
NIO   34.69 (-1.95%)
CGC   14.01 (+0.72%)
GE   106.29 (+2.40%)
MU   74.22 (+0.23%)
AMD   103.83 (-1.86%)
T   27.45 (+1.18%)
F   14.07 (+2.10%)
ACB   5.98 (+0.50%)
DIS   176.40 (+0.23%)
PFE   43.83 (-0.25%)
BA   227.69 (+2.85%)
BAC   43.29 (+2.73%)
QQQ   368.40 (-1.32%)
AAPL   144.18 (-1.86%)
MSFT   293.79 (-1.86%)
FB   348.56 (-1.25%)
GOOGL   2,812.17 (-1.13%)
TSLA   773.15 (-0.16%)
AMZN   3,351.30 (-2.17%)
NVDA   214.13 (-3.03%)
BABA   145.61 (+0.37%)
NIO   34.69 (-1.95%)
CGC   14.01 (+0.72%)
GE   106.29 (+2.40%)
MU   74.22 (+0.23%)
AMD   103.83 (-1.86%)
T   27.45 (+1.18%)
F   14.07 (+2.10%)
ACB   5.98 (+0.50%)
DIS   176.40 (+0.23%)
PFE   43.83 (-0.25%)
BA   227.69 (+2.85%)
BAC   43.29 (+2.73%)

Moderna Price Target, Predictions & Analyst Ratings

$418.80
-11.34 (-2.64 %)
(As of 09/27/2021 09:45 AM ET)
Add
Compare
Today's Range
$416.18
$433.38
50-Day Range
$307.33
$484.47
52-Week Range
$65.49
$497.49
Volume46,037 shs
Average Volume13.52 million shs
Market Capitalization$169.05 billion
P/E Ratio52.22
Dividend YieldN/A
Beta1.48

Moderna (NASDAQ:MRNA) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Hold
Based on 15 Analyst Ratings

Analyst Price Target Consensus

$195.62

High PT$337.00
Average PT$195.62
Low PT$80.00
TypeCurrent
9/27/20 to 9/27/21
1 Month Ago
8/28/20 to 8/28/21
3 Months Ago
6/29/20 to 6/29/21
1 Year Ago
9/28/19 to 9/27/20
Consensus Rating
Hold
Hold
Hold
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
8 Buy rating(s)
14 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
6 Hold rating(s)
2 Hold rating(s)
Sell
3 Sell rating(s)
3 Sell rating(s)
3 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$195.62$184.31$164.31$87.53
Price Target Upside-53.29% Downside9.56% Upside9.39% Upside28.52% Upside
Get Moderna Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Moderna (NASDAQ:MRNA) vs. Its Competitors

TypeModernaMedical CompaniesS&P 500
Consensus Rating Score
2.13
2.72
2.56
Consensus RatingHoldBuyBuy
Price Target Upside124.89% Upside7.29% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
174
73.11%
Underperform Votes
64
26.89%
Avg. Outperform Votes
177
67.30%
Avg. Underperform Votes
86
32.70%
Avg. Outperform Votes
829
69.49%
Avg. Underperform Votes
364
30.51%

Moderna (NASDAQ:MRNA) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/12/2021SVB Leerink
Reiterated RatingSell
9/7/2021Morgan Stanley
Boost Price TargetEqual Weight$190.00 ➝ $337.00-20.73%
8/6/2021Piper Sandler
DowngradeOverweight ➝ Neutral
8/5/2021Oppenheimer
DowngradeOutperform ➝ Market Perform
7/15/2021Jefferies Financial Group
Michael Yee
Boost Price TargetPositive ➝ Hold$170.00 ➝ $250.00+1.35%
7/7/2021Chardan Capital
M. Barcus
Reiterated RatingBuy
6/24/2021Argus
Boost Price TargetBuy$200.00 ➝ $230.00+8.47%
5/7/2021Barclays
Boost Price TargetOverweight$178.00 ➝ $194.00+20.87%
5/7/2021The Goldman Sachs Group
Boost Price TargetBuy$206.00 ➝ $228.00+42.06%
4/16/2021Needham & Company LLC
Reiterated RatingHold
2/26/2021Brookline Capital Management
Boost Price TargetBuy$180.00 ➝ $205.00+31.52%
2/26/2021Bank of America
Geoff Meacham
Reiterated RatingSell$140.00-5.65%
2/1/2021Wells Fargo & Company
Boost Price TargetOverweight ➝ Equal Weight$129.00 ➝ $145.00-16.26%
11/17/2020Redburn Partners
Initiated CoverageSell
11/17/2020BMO Capital Markets
DowngradeOutperform ➝ Market Perform$109.00+11.28%
8/6/2020JPMorgan Chase & Co.
Reiterated RatingHold
7/27/2020SunTrust Banks
Welles Fitzpatrick
Initiated CoverageBuy$120.00+50.17%
5/11/2020Roth Capital
Boost Price TargetBuy$41.00 ➝ $68.00+14.77%
1/2/2020Piper Jaffray Companies
Edward Tenthoff
Initiated CoverageOverweight$24.00+26.48%
(Data available from 9/27/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)
speech bubbles
speech bubbles











Moderna (NASDAQ:MRNA) Analyst Ratings Frequently Asked Questions

What is Moderna's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for Moderna stock is Hold based on the current 3 sell ratings, 7 hold ratings and 5 buy ratings for MRNA. The average twelve-month price target for Moderna is $195.62 with a high price target of $337.00 and a low price target of $80.00. Learn more on MRNA's analyst rating history

Do Wall Street analysts like Moderna more than its competitors?

Analysts like Moderna stock less than the stock of other Medical companies. The consensus rating for Moderna is Hold while the average consensus rating for medical companies is Buy. Learn more on how MRNA compares to other companies

Do MarketBeat users like Moderna more than its competitors?

MarketBeat users like Moderna stock more than the stock of other Medical companies. 73.11% of MarketBeat users gave Moderna an outperform vote while medical companies recieve an average of 67.30% outperform votes by MarketBeat users.

Is Moderna being downgraded by Wall Street analysts?

Over the previous 90 days, Moderna's stock had 2 downgrades by analysts.

Does Moderna's stock price have much upside?

According to analysts, Moderna's stock has a predicted upside of 1.73% based on their 12-month price targets.

What analysts cover Moderna?

Moderna has been rated by Chardan Capital, Jefferies Financial Group, Morgan Stanley, Oppenheimer, Piper Sandler, and SVB Leerink in the past 90 days.

This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.